TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27749954
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose capsules) plus 5 doses of 100 mL decaffeinated coffee
Study: 23131971
Drug: Health and
Normalized name: Culturelle Health and Wellness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health and wellness therapy group (n = 37)
Study: 19944581
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol xinafoate (FSC) 100/50 microg twice daily
Study: 19944581
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 microg twice daily
Study: 11448906
Drug: Suramin treatment
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin treatment in patients with HRPC
Study: 9649013
Drug: Simvastatin 10
Normalized name: simvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 10 mg/day plus Ursodeoxycholic acid 600 mg/day (group 1)
Study: 9649013
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid 600 mg/day (group 2)
Study: 8596756
Drug: Uraemic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uraemic group (HD treatment)
Study: 2574054
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg acrivastine
Study: 2570000
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine at 1 h before challenge
Study: 2570000
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine at 2 h before challenge
Study: 2570000
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg acrivastine at 1 and 2 h before challenge
Study: 1192697
Drug: Dipeptide glycyl‐L‐alanine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipeptide glycyl‐L‐alanine and its constituent amino acids
Study: 1192697
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride solution (150 mmol/l)
Study: 27465676
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy added to standard treatment (repositioning and an orthotic helmet)
Study: 27465676
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (repositioning and an orthotic helmet)
Study: 27465676
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy added to standard treatment
Study: 22055763
Drug: Dose-dense weekly
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose-dense weekly paclitaxel (ddT) plus carboplatin
Study: 22055763
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including treatment administration (ddT)
Study: 22055763
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including treatment administration (q3T)
Study: 19578177
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) patients
Study: 14693625
Drug: Intrathecal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal meperidine (0.2 mg/kg)
Study: 31081593
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors or SGLT-1/2 inhibitors as adjunct to insulin
Study: 31081593
Drug: SGLT-2 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT-2 inhibitors or SGLT-1/2 inhibitors
Study: 21091369
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac plus iliac crest normal saline infusion
Study: 21091369
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac plus iliac crest bupivacaine infusion
Study: 21091369
Drug: Iliac crest
Normalized name: Crest
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iliac crest bupivacaine infusion alone
Study: 11597291
Drug: Ramipril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (up to 10 mg/d, n = 2837)
Study: 11479247
Drug: Ramipril (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (up to 10 mg/d)
Study: 1790748
Drug: Timolol 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.1% eye drops, applied twice daily for one week before surgery
Study: 1790748
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% eye drops, applied twice daily for one week before surgery
Study: 1790748
Drug: Placebo eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops, applied twice daily for one week before surgery
Study: 6803819
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate (800 mg/day in the first week, 1 g/day in the second week)
Study: 25892407
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with daily wake up
Study: 20973685
Drug: Bivalirudin 2
Normalized name: bivalirudin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin 2 mg/hour
Study: 20973685
Drug: Heparin 400
Normalized name: heparin 40000 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 400 units/hour
Study: 18621591
Drug: 100mg trazodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg trazodone tablet formulation
Study: 10347132
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral therapy (Control)
Study: 8817829
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (Engerix‐B, 10 micrograms dose‐1)
Study: 8817829
Drug: Haemophilus influenzae
Normalized name: HAEMOPHILUS INFLUENZAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae type b (Hib) conjugate vaccine
Study: 28843031
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (OGTT) prescribed to individuals scoring over 13 points on FINDRISC; 2.8% of population survey and 75.4% of opportunistic survey participants took the OGTT.
Study: 28843031
Drug: Evaluation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of insulin resistance in individuals with prediabetes.
Study: 17584825
Drug: Sequential regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential regimen (specifics not provided)
Study: 17584825
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (specifics not provided)
Study: 16132888
Drug: Ventilation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation with lower tidal volume (V(T) of 6 ml/kg ideal body weight)
Study: 16132888
Drug: Ventilation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilation with higher tidal volume (V(T) of 12 ml/kg ideal body weight)
Study: 12034024
Drug: IFN-alpha2a (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2a (3 x 10(6) IU) three times weekly for 8-16 weeks
Study: 12034024
Drug: IFN-alpha2a (1.5-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2a (1.5-6 x 10(6) IU) three times weekly for 12 months
Study: 12034024
Drug: IFN-alpha2a re-administration
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2a re-administration after discontinuation
Study: 12034024
Drug: IFN-alpha2a treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-alpha2a treatment
Study: 2147175
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg/day) for 36 weeks followed by a placebo period of 4 weeks
Study: 2147175
Drug: Encapsulated fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated fish oil (9 g/day) for 36 weeks with a subsequent period of 4 weeks in which fish oil placebo was given
Study: 2147175
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg/day) for 12 weeks, propranolol plus fish oil capsules (9 g/day) for 12 weeks, propranolol plus fish oil placebo for 12 weeks
Study: 6972101
Drug: Antrafenine 450
Normalized name: Antrafenine
DrugBank: Antrafenine (DB01419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antrafenine 450 mg/day
Study: 6972101
Drug: Antrafenine 900
Normalized name: Antrafenine
DrugBank: Antrafenine (DB01419)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antrafenine 900 mg/day
Study: 6972101
Drug: Aspirin 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 1.8 g/day
Study: 31046719
Drug: Endurance plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance plus balance training (twice weekly over 12 weeks)
Study: 31046719
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training (twice weekly over 12 weeks)
Study: 23644816
Drug: Telephone based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone based cognitive behavioral therapy (T-CBT)
Study: 23644816
Drug: Face-to-face therapy
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face therapy (f2f)
Study: 22852117
Drug: Curcumin 1000
Normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 1000 mg twice daily
Study: 15526058
Drug: rabies vaccine
Normalized name: RABIES VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabies vaccine (control)
Study: 11251139
Drug: Lidocaine (2%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (2%, 0.5 mL) mixed with radiopaque fluid (0.25 mL) injected after verifying target location using sensory and motor electrostimulation.
Study: 9684395
Drug: Full intervention
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full intervention (referral to treatment)
Study: 25703058
Drug: Gel cuff
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel cuff applied to the most severely affected lower leg skin for 30 min daily
Study: 18772244
Drug: Testosterone supplements
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone supplements
Study: 16438129
Drug: Artekin (dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg) given once a day for 3 days (Group B)
Study: 16438129
Drug: Artesunate 4
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day orally once a day for 3 days (Group A)
Study: 16438129
Drug: Artekin (dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artekin (dihydroartemisinin 40 mg and piperaquine 320 mg)
Study: 16438129
Drug: Artesunate 4
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artesunate 4 mg/kg/day and mefloquine 8 mg/kg/day
Study: 12903625
Drug: Pentaglobin (infused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (infused intravenously at 12 mL/h for 3 days)
Study: 12903625
Drug: Previous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous treatment period without Pentaglobin
Study: 7564347
Drug: UP 269-6
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP 269-6 (180 mg)
Study: 7564347
Drug: UP 269-6
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: UP 269-6 (>= 40 mg)
Study: 1939923
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment
Study: 31770456
Drug: Itraconazole (P-glycoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (P-glycoprotein inhibitor)
Study: 30908592
Drug: Restrictive oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive oxygen therapy (no supplemental oxygen if SpO2 ≥ 94%, n=21)
Study: 30908592
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen therapy (intubated patients: FiO2 1.0 in trauma bay, 0.8-1.0 elsewhere; spontaneously breathing patients: 15 L/min via non-rebreather mask, n=20)
Study: 28394418
Drug: Every‐2‐week dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every‐2‐week dosing regimen of Peginterferon beta‐1a
Study: 26081864
Drug: Rehab-let (touchscreen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehab-let (touchscreen tablet self-training protocol)
Study: 23569345
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg IL‐1Ra via ear vein 18 h, 2 d and 4 d after D‐gal induction (Group B)
Study: 23569345
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg IL‐1Ra via ear vein 18 h after D‐gal induction, MSCs transplantation at 24 h after D‐gal induction, and 2 mg/kg IL‐1Ra via ear vein 1 d and 3 d after surgery (Group D)
Study: 23569345
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL saline via portal vein 24 h after D‐gal induction (Group A)
Study: 23569345
Drug: Approximately 1
Normalized name: (CYS74>SER,ALA245>THR)ADENOSINE DEAMINASE (BOS TAURUS, BOVINE)-(1-356)-PEPTIDE, PRODUCED IN ESCHERICHIA COLI, SUBSTITUTED ON N2 OF THE N-TERMINAL ALANYL RESIDUE (A1) AND ON N6 OF LYSYL RESIDUES (K) WITH AN AVERAGE OFAPPROXIMATELY 13 .OMEGA.-METHOXYPOLY(O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1 × 10(8) GFP‐MSCs suspended in 40 mL normal saline via portal vein 24 h after D‐gal induction (Group C)
Study: 22143217
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care education for caregivers (6 weeks duration)
Study: 22143217
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral care from control group caregivers
Study: 20795842
Drug: Atenolol therapy
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol therapy
Study: 11474773
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sodium rabeprazole
Study: 9604880
Drug: Nicotinamide (slow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (slow release, 1.2 g x m(‐2) x day(‐1))
Study: 26817206
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D supplement (2,000 IUs/day)
Study: 23284036
Drug: Protocolized patient‐tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolized patient‐tailored treatment (PPT) of symptoms
Study: 19084937
Drug: 4-week pegylated
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Study: 19084937
Drug: 12-week pegylated
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week pegylated interferon alpha-2a (peg-IFN-alpha 2a) monotherapy, 180 microg or 90 microg once weekly
Study: 18039239
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group physical therapy (PT)
Study: 14979498
Drug: Ipratropium (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (2 puffs of 20 microg administered four times daily)
Study: 9652994
Drug: MFP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP plus calcium (20 mg of equivalent fluoride + 1000 mg calcium)
Study: 22980891
Drug: L‐FVOO (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐FVOO (250 mg total phenols/kg)
Study: 22980891
Drug: M‐FVOO (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐FVOO (500 mg total phenols/kg)
Study: 22980891
Drug: H‐FVOO (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: H‐FVOO (750 mg total phenols/kg)
Study: 17244785
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg daily (PIO)
Study: 11965508
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60 mg RE to mothers and 7.5 mg RE to infants with each OPV dose)
Study: 9825815
Drug: Increased doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased doses of tacrolimus (median increase of 1.89-fold, range: 1.2-5 mg)
Study: 2466045
Drug: Octreotide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (50 micrograms, twice daily, sc)
Study: 21955635
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in the same way
Study: 24196330
Drug: Nd:YAG 1440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG 1440 nm laser treatment
Study: 18203019
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 once weekly for 4 weeks
Study: 18203019
Drug: Rituximab in
Normalized name: rituximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab in combination with interferon alpha-2a (IFN) (n = 33)
Study: 11812685
Drug: Full-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose aprotinin regimen
Study: 10910828
Drug: Half-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose aprotinin regimen
Study: 8760643
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of lorazepam, orally, one hour before induction of anaesthesia
Study: 1425205
Drug: Seaprose (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seaprose (60 mg/8 h) plus erythromycin (500 mg/8 h)
Study: 1425205
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg/8 h) plus placebo
Study: 3967167
Drug: Intravenous dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dacarbazine plus intradermal injection of the methanol‐extracted residue of bacillus Calmette‐Guerin (BCG)
Study: 3967167
Drug: Intravenous dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dacarbazine alone
Study: 21190639
Drug: Medication switches
Normalized name: witch hazel Medicated Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication switches
Study: 15673878
Drug: Small-dose IV
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose IV ketamine (0.5 mg/kg bolus followed by 3 mcg/kg/min during surgery and 1.5 mcg/kg/min for 48 hours)
Study: 15673878
Drug: Small-dose IV
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-dose IV ketamine
Study: 8866316
Drug: Demineralized freeze‐dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demineralized freeze‐dried bone allograft reconstituted with 50 mg/ml tetracycline (DFDBA + TCN)
Study: 1333782
Drug: Single, high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, high dose of aspirin
Study: 6474351
Drug: Aspirin 325
Normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 325 mg and dipyridamole 75 mg
Study: 24587006
Drug: Subcutaneous palonosetron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous palonosetron
Study: 21769988
Drug: Information about
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Information about the association between cognitive problems and chemotherapy
Study: 21769988
Drug: No information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: No information about the association between cognitive problems and chemotherapy
Study: 18093331
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavior therapy (8 weekly lessons, support by e-mail)
Study: 18093331
Drug: Internet-based problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based problem-solving therapy (5 weekly lessons, support by e-mail)
Study: 16357163
Drug: GDNF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDNF treatment in pancreatic cancer cells with G691S RET polymorphism
Study: 16357163
Drug: GDNF treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDNF treatment in pancreatic cancer cells without specific mention of RET polymorphism
Study: 10919583
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 1-3 mg/kg daily
Study: 1526096
Drug: i.m. immunoglobulins
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.m. immunoglobulins and oral polyvalent bacterial vaccine
Study: 1526096
Drug: vaccine only
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccine only
Study: 29154271
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue biopsies from AD patients
Study: 29154271
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue biopsies from cognitively healthy proxies
Study: 24041789
Drug: 7.5‐µg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5‐µg dose of A/Vietnam vaccine
Study: 24041789
Drug: Booster immunization
Normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster immunization with A/Indonesia(H5N1) vaccine
Study: 20085866
Drug: Plasma nucleosome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma nucleosome levels before therapy cycles 2 and 3
Study: 16259492
Drug: Monthly support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly support group or monthly phone call from a nurse (follow-up conditions)